1. Eveborn GW, Schirmer H, Heggelund G Lunde P, Rasmussen K. The evolving epidemiology of valvular aortic stenosis. The Tromsø study. Heart. 2013;99(6):396–400. doi:10. 1136/heartjnl-2012–302265
2. Van Bogerijen GH, Tolenaar JL, Grassi V, Lomazzi C, Segreti S, Rampoldi V et al. Biomarkers in TAA-the Holy Grail. Prog Cardiovasc Dis. 2013;56(1):109–15. doi:10.1016/j. pcad.2013.05.004
3. Farré N, Gómez M, Molina L, Cladellas M, Blé M, Roqueta C et al. Prognostic value of NT-proBNP and an adapted monin score in patients with asymptomatic aortic stenosis. Rev Esp Cardiol (Engl Ed). 2014;67(1):52–7. doi:10.1016/j.rec.2013.06.020
4. Tzemos N, Lyseggen E, Silversides C, Jamorski M, Tong JH, Harvey P et al. Endothelial function, carotid-femoral stiffness, and plasma matrix metalloproteinase-2 in men with bicuspid aortic valve and dilated aorta. J Am Coll Cardiol. 2010;55(7):660–8. doi:10.1016/j.jacc.2009.08.080
5. Gavriliuk N, Druzhkova T, Irtyuga O, Zhloba A, Subbotina T, Uspenskiy V et al. Asymmetric dimethylarginine in patients with ascending aortic aneurysms. Aorta (Stamford). 2016;4 (6):219–226. doi:10.12945/j.aorta.2016.16.025
6. Ali OA, Chapman M, Nguyen TH, Chirkov Y, Heresztyn T, Mundisugih J et al. Interactions between inflammatory activation and endothelial dysfunction selectively modulate valve disease progression in patients with bicuspid aortic valve. Heart. 2014;100 (10):800–5. doi:10.1136/heartjnl-2014–305509
7. Tsikas D, Wu G. Homoarginine, arginine, and relatives: analysis, metabolism, transport, physiology, and pathology. Amino Acids. 2015;47(9):1697–1702. doi:10.1007/s00726–015–2055–5
8. März W, Meinitzer A, Drechsler C, Pilz S, Krane V, Kleber ME et al. Homoarginine, cardiovascular risk, and mortality. Circulation. 2010;122(10):967–75. doi:10.1007/s00726–015–2055–5
9. Drechsler C, Meinitzer A, Pilz S, Krane V, Tomaschitz A, Ritz E et al. Homoarginine, heart failure, and sudden cardiac death in haemodialysis patients. Eur J Heart Fail. 2011;13(8):852–59. doi:10.1093/eurjhf/hfr056
10. Pilz S, Meinitzer A, Tomaschitz A, Drechsler C, Ritz E, Krane V et al. Low homoarginine concentration is a novel risk factor for heart disease. Heart. 2011;97 (15):1222–27. doi:10.1136/ hrt.2010.220731
11. Choe CU, Atzler D, Wild PS, Carter AM, Boger RH, Ojeda F et al. Homoarginine levels are regulated by L-arginine: glycine amidinotransferase and affect stroke outcome: results from human and murine studies. Circulation. 2013;128(13):1451–61. doi:10.1161/ CIRCULATIONAHA.112.000580
12. Жлоба А. А., Субботина Т. Ф., Алексеевская Е. С., Моисеева О. М., Гаврилюк Н. Д., Иртюга О. Б. и соавт. Уровень циркулирующего PGC1a при сердечно-сосудистых заболеваниях. Биомедицинская химия. 2016;62(2):198–205. doi:10.18097/PBMC20166202198.
13. Жлоба А. А., Субботина Т. Ф., Алексеевская Е. С., Моисеева О. М., Дружкова Т. А., Жидулева Е. В. и соавт. Метаболический предшественник карнитина триметил-L-лизин и метилированные продукты аргинина у пациентов с заболеваниями сердечно-сосудистой системы. Артериальная гипертензия. 2015;21(6):587–94. doi:10.18705/1607–419X-2015–21–6-587– 594.
14. Davids M, Ndika JD, Salomons GS, Blom HJ, Teerlink T. Promiscuous activity of arginine: glycine amidi notransferase is responsible for the synthesis of the novel cardiovascular risk factor homoarginine. FEBS Lett. 2012;586 (20):3653–7. doi:10.1016/j.febslet.2012.08.020
15. Jaÿwińska-Kozuba A, Martens-Lobenhoffer J, Kruszelnicka O, Rycaj J, Chyrchel B, Surdacki A et al. Opposite associations of plasma homoarginine and ornithine with arginine in healthy children and adolescents. Int J Mol Sci. 2013;14(11):21819– 21832. doi:10.3390/ijms141121819
16. Chau K, Elefteriades JA. Ascending thoracic aortic aneurysms protect against myocardial infarctions. Int J Angiol. 2014;23(3):177–82. doi:10.1055/s-0034–1382288
17. Apostolova N, Victor MV. Molecular Strategies for Targeting Antioxidants to Mitochondria: Therapeutic Implications. Antioxid Redox Signal. 2015; M22(8):686–729. doi:10.1089/ars.2014.5952